Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00348361 |
This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.
Condition | Intervention | Phase |
---|---|---|
Allergic Rhinitis |
Drug: Fluticasone Propionate |
Phase I |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Study to Validate Key Therapeutic Targets and Biomarkers During Allergen Exposure in Subjects With Allergic Rhinitis |
Estimated Enrollment: | 48 |
Study Start Date: | April 2005 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Netherlands | |
GSK Investigational Site | |
AMSTERDAM, Netherlands, 1105 AZ | |
United Kingdom | |
GSK Investigational Site | |
London, United Kingdom, WC1X 8DA |
Study Director: | GSK Clinical Trials, MD,MSc, FPPM | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | ELR100710 |
Study First Received: | June 30, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00348361 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Hay fever biomarkers |
Fever Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases |
Rhinitis, Allergic, Seasonal Fluticasone Rhinitis |
Anti-Inflammatory Agents Respiratory System Agents Autonomic Agents Therapeutic Uses Physiological Effects of Drugs Anti-Asthmatic Agents |
Anti-Allergic Agents Peripheral Nervous System Agents Dermatologic Agents Bronchodilator Agents Pharmacologic Actions Nose Diseases |